Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

October 5, 2020

Read the press release in Swedish: 

Download attachment (pdf)
< Back to press releases
Elicera Therapeutics AB is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.

Org.nr: 556966-4955
Elicera Therapeutics AB (publ)
World Trade Center Göteborg
Mässans gata 10, floor 7
412 51, Göteborg
info@elicera.com
+46 (0)70-331 90 51‬
Integrity Policy
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.